Why Bay Area's XOMA Surged 700% in 2017 by Not Making Drugs Post author:Sam Post published:January 25, 2018 Post category:BioPharma The company burned through $1.2B and never brought a drug to market in its 37 years. Source: BioSpace You Might Also Like Former PTC Therapeutics Exec Jumps Ship to Orchard Therapeutics as CEO August 9, 2017 GlaxoSmithKline's Nucala Wins FDA Approval for EGPA December 11, 2017 InVivo Therapeutics Announces New Patient Enrollment Into The INSPIRE Study At June 26, 2017
